Saturday 17 October 2026
Export ADMA’s income statement to Excel — free account
ADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1.98%, EPS grew 21.4%, free cash flow grew 19.7% and total debt rose 140.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
10.68
0.05
−0.47%
Follow ADMA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
11.63 | 13.06 | 29.90 | 16.85 |
+8 more quarters Free account |
P/S ratio |
3.73 | 4.17 | 8.52 | 7.16 | |
P/FCF ratio |
16.44 | 18.90 | 158.03 | 86.14 | |
P/Operating CF |
64.67 | 36.52 | 121.96 | 263.14 | |
P/B ratio |
4.68 | 5.45 | 9.11 | 8.11 | |
Price to Tangible BV |
4.73 | 5.51 | 9.19 | 8.19 | |
EV/Sales |
3.85 | 4.29 | 8.50 | 7.20 | |
EV/EBITDA |
8.48 | 9.80 | 21.66 | 20.02 | |
EV/Operating CF |
14.43 | 17.06 | 86.02 | 54.12 | |
EV/FCF |
16.98 | 19.45 | 157.61 | 86.59 | |
Quick Ratio |
3.62 | 3.73 | 3.54 | 3.52 | |
Current Ratio |
6.97 | 6.95 | 6.71 | 7.13 | |
Net Debt/EBITDA |
1.16 | 1.03 | (0.18) | 0.34 | |
Debt/Assets |
29.07% | 30.06% | 12.17% | 13.98% | |
Debt/Equity |
0.49 | 0.51 | 0.16 | 0.18 | |
Asset Turnover |
0.82 | 0.87 | 0.92 | 1.02 | |
Operating CF/Net income |
0.78 | 1.29 | 0.72 | 0.36 | |
Capex/Depreciation |
(3.74) | 1.21 | (0.58) | (6.66) | |
Interest Coverage |
15.32 | 27.75 | 38.59 | 30.45 | |
Research and Development Expense of Revenue |
4.83% | 2.27% | 0.99% | 1.14% | |
Selling, General and Administrative Expense of Revenue |
21.49% | 23.36% | 16.89% | 16.22% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
4.93% | 5.53% | 3.87% | 3.76% | |
Graham Net Nets |
0.13 | 0.11 | 0.07 | 0.08 | |
Graham Number |
5.38 | 5.07 | 5.24 | 5.95 | |
Earnings Yield |
8.60% | 7.66% | 3.34% | 5.93% | |
Free Cash Flow Yield |
6.08% | 5.29% | 0.63% | 1.16% | |
Revenue per Share |
0.55 | 0.49 | 0.58 | 0.56 | |
Operating CF per Share |
0.13 | 0.25 | 0.15 | 0.06 | |
Capex per Share |
(0.03) | 0.01 | (0.01) | (0.06) | |
Free Cash Flow per Share |
0.10 | 0.26 | 0.14 | 0.00 | |
Cash per Share |
0.60 | 0.59 | 0.37 | 0.26 | |
Shareholders Equity per Share |
1.79 | 1.65 | 2.00 | 1.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.79 | 1.65 | 2.00 | 1.81 | |
Free Cash Flow |
22.28 | 60.65 | 34.36 | (1.07) | |
Working Capital |
452.45 | 437.63 | 396.97 | 346.17 | |
Capital Expenditures |
(7.26) | 2.40 | (1.28) | (14.37) | |
Net Current Asset Value |
252.20 | 236.31 | 319.59 | 265.15 | |
EV/EBIT |
8.79 | 10.19 | 22.64 | 21.05 | |
Capex to Sales |
0.06 | (0.02) | 0.01 | 0.11 | |
Price to Operating Income |
8.51 | 9.90 | 22.70 | 20.94 | |
| Other line items | |||||
Average Receivables |
123.98 | 117.64 | 104.21 | 93.91 | |
Average Payables |
30.75 | 20.57 | 21.37 | 20.02 | |
Average Inventory |
215.39 | 197.14 | 188.35 | 184.23 | |
Average Assets |
621.30 | 587.88 | 556.46 | 479.65 | |
Average Common Equity |
403.27 | 381.87 | 413.17 | 331.54 |
Columns are period end dates